News
Top 3 Enroller Studywide: Achieving 267% of the Goal in Phase 2 Obesity & T2DM Trial
DelRicht Research is proud to highlight the exceptional performance of Dr. Patrick Dennis and his team at Touro Medical Center in New Orleans, LA, whose site achieved top-tier enrollment results in a Phase 2 clinical trial focused on obesity and Type 2 diabetes (T2DM). Their ability to rapidly activate, enroll,...
What Happens When a Trial is Cancelled or Delayed: The Impact on Sites & Site Networks
Clinical research has always evolved through change. New science, shifting priorities, and even the difficult decisions to pause or cancel a study are part of the process that propels medicine forward. Recent insights from GlobalData show that roughly 4.7 percent of registered clinical trials are terminated, most often for reasons...
Dr. Patrick Dennis Featured as an Author on Recent Phase 2 Hypertension Manuscript
Uncontrolled hypertension remains a significant public health challenge, affecting millions of adults worldwide and increasing the risk of heart disease, stroke, and kidney failure. A recent publication, “Efficacy of Tonlamarsen in Patients with Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial,” provides important insight into a novel approach to...
Driving Success in Migraine Research: DelRicht Delivers Expertise and Enrollment Excellence
As migraine research continues to evolve, driven by increasing patient demand and a growing therapeutic pipeline, DelRicht Research stands out as a trusted partner for sponsors and CROs seeking both speed and precision. With more than 19 migraine trials completed over the past eight years, 740+ participants enrolled, and 17...
DelRicht Completes Enrollment as the Single Site Network in Recent COVID Study
DelRicht Research is proud to highlight the performance of its multi-site network in a U.S.-based Phase 3b/4 COVID-19 booster vaccine trial, where speed, coordination, and adaptability were critical to success. Exclusively selected as the site network for this study, DelRicht was tasked with enrolling both adolescent and adult populations across...
Dr. Robert Springer Featured as an Author on Recent COVID-19 Manuscript
The fight against COVID-19 continues to evolve as new variants emerge and public health priorities adapt. A recent publication, “Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccines,” offers encouraging insight into how Moderna’s next-generation vaccines perform against the LP.8.1 subvariant and other circulating strains. DelRicht Research investigator Dr. Robert...
Dr. Newton Achieves First Activation and First Patient Screened in Hypertension Trial
CHARLESTON, SC – DelRicht Research is proud to recognize Dr. E. Marshall Newton and the Charleston research team for achieving early, study-defining milestones in a Phase 2b clinical trial evaluating a novel treatment for hypertension. Through focused coordination and operational preparedness, the site achieved first site activated and first patient...
Dr. Ira Thorla Contributes to Phase 2 Study Evaluating Combination Therapy for Vitiligo
Vitiligo is a chronic autoimmune condition that causes loss of pigmentation and affects millions worldwide, often impacting confidence, quality of life, and emotional well-being. As research into new treatment combinations accelerates, a recently published Phase 2 study offers encouraging insight into how ruxolitinib 1.5% cream and narrow-band UVB phototherapy (NB-UVB)...
Dr. Campion Achieves First Patient Screened & Enrolled in Phase III SAD Trial
NEW ORLEANS, LA – We are proud to recognize Dr. Caroline Campion and the exceptional research team in New Orleans for achieving a remarkable series of milestones in a Phase 3 clinical trial for Social Anxiety Disorder (SAD). Through seamless coordination, strong patient engagement, and precise operational execution, the site...
150% of Enrollment Goal Achieved Across Four Sites in a Phase 3 Migraine Trial
DelRicht Research is proud to highlight the outstanding performance of our site teams across Atlanta, Gulfport, New Orleans, and Tulsa in a recent Phase 3 clinical trial for migraine. Designed to evaluate the safety and efficacy of an investigational therapy in adults ages 18-70, the study enrolled 400 participants across...
